Alterity Therapeutics Announced Alignment With FDA On Pivotal Phase 3 ATH434 Program In Multiple System Atrophy; FDA Agrees To Phase 3 Design Including UMSARS Part I As Primary Endpoint

Multiple System Atrophy Clinical Trial Pipeline Gains Momentum: 22+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

The multiple system atrophy (MSA) clinical trial pipeline is experiencing significant momentum with 22+ companies developing 24+ pipeline drugs. The pipeline is diversifying beyond traditional approaches to include oral small molecules, cell replacement therapies, gene therapies, and next-generation alpha-synuclein inhibitors. Recent developments include Alterity Therapeutics achieving FDA alignment on Phase III for ATH434, Teva receiving Fast Track designation for TEV-56286, and iRegene Therapeutics enrolling the first patient in a randomized controlled trial for NouvNeu004 in China.

Alterity Therapeutics shares are trading higher after the company announced it was granted a new composition of mater patent for ATH434 by the U.S. Patent and Trademark Office.

Alterity Therapeutics Secures Key US Patent for Lead Asset

Alterity Therapeutics secured a USPTO patent for ATH434, extending market protection for its neurodegenerative drug candidate to 2045.

Alterity Therapeutics Secures New US Patent for ATH434 Extending Protection to At Least 2045, And Enhancing Its Commercial Potential